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Transcriptional repressionERa, a critical transcriptional factor for breast cancer proliferation, is regulated by a complex bind-
ing repertoire that includes coactivators and corepressors. Here, we identiﬁed a novel class of ERa
coregulator called CAC1. The CoRNR box of CAC1 was required for the binding to and inactivation
of ERa. CAC1 also associated with histone demethylase LSD1 and suppressed LSD1-enhanced ERa
activity. CAC1 impaired recruitment of ERa and LSD1 to the ERa-responsive promoter, leading to
greater H3K9me3 accumulation. This effect was reversed by CAC1 depletion. Finally, CAC1 increased
paclitaxel-induced cell death in ERa-positive MCF7 cells, which are paclitaxel-resistant. Overall, our
study provides the ﬁrst evidence that CAC1, associated with LSD1, functions as an ERa corepressor,
implicating a potential antitumor target in ERa-positive breast cancer.
Structured summary of protein interactions:
ER-alpha physically interacts with CAC1 by anti tag coimmunoprecipitation (View Interaction: 1, 2, 3)
LSD1 physically interacts with CAC1 by anti tag coimmunoprecipitation (View interaction)
CAC1 binds to ER-alpha by pull down (View interaction)
CAC1 and ER-alpha colocalize by ﬂuorescence microscopy (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Estrogen receptor alpha (ERa) belongs to the nuclear hormone
receptor (NR) superfamily and mediates the effects of the steroid
hormone estrogen 17b-estradiol (E2) as a ligand-dependent tran-
scription factor [1]. ERa is involved in a diverse range of physiolog-
ical processes in various tissues, including growth, differentiation,
and reproduction, and plays an important role in the development
and progression of breast cancer [2]. Two ER subtypes, ERa and
ERb, have been identiﬁed. The subtypes are encoded by different
genes and regulate the expression of different target genes [3].
However, they possess a modular structure common to most NRs
consisting of an N-terminal, ligand-independent transcriptional
activation function 1 (AF-1), a conserved DNA-binding domain
(DBD)-containing zinc-ﬁnger motif, a hinge region, and a C-terminal ligand-binding domain that overlaps with a second tran-
scriptional activation function 2 (AF-2) [4]. E2-bound ERa forms
homodimers and binds to estrogen response elements (EREs) in
the promoter region of target genes and regulates gene expression
by recruiting various coregulators, such as general transcription
factors, coactivators, corepressors, and histone modiﬁers [5].
Coactivators are required for ERa transcriptional activation,
including steroid receptor coactivator 1–3 (SRC1–3; a p160 family
member), CREB-binding protein (CBP)/p300 and PCAF [histone
acetyltransferases (HATs)], and coactivator-associated arginine
methyltransferase 1 (CARM1) [6]. NR corepressors [e.g., nuclear
receptor corepressor (NCoR) and silencing mediator of retinoid
and thyroid hormone receptors (SMRT)] usually bind receptors in
the absence of ligand and actively repress target gene transcription
by recruiting large repressor complexes, including histone
deacetylases (HDACs) and nucleosome remodeling complex NURD
[7,8]. Different from other NRs, antagonist-loaded ERa binds to
target gene EREs and recruits NCoR and SMRT corepressor
complexes for transcriptional repression [9,10]. While the ERa
coactivator molecular mechanism is well known, the role of
ligand-independent corepressors other than NCoR and SMRT
remains unclear.
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ocaited cullin (CAC1), as a ligand-independent ERa corepressor.
In this study, we demonstrated that CAC1 directly binds to ERa
and suppresses ERa-mediated transcriptional activity in the ab-
sence or presence of E2. CAC1 also interacted with LSD1 and alle-
viated the ERa coactivator function. Moreover, we showed that
CAC1 and LSD1 reciprocally modulate paclitaxel-mediated cell
death in ERa-positive, paclitaxel-resistant MCF7 cells. These data
suggest that CAC1 negatively regulates ERa activity and provides
a beneﬁcial means of chemotherapy for paclitaxel-resistant breast
cancers.
2. Materials and methods
2.1. Plasmids and cloning
All cDNAs were constructed according to standard methods and
veriﬁed by sequencing. CAC1 cDNA full-length and deletion mu-
tants were ampliﬁed by PCR and subcloned into suitable vectors
[Myc-tagged pcDNA3, pEGFP-C3 (BD Biosciences), pGEX4T-1 (GE
Healthcare)].
2.2. Cell lines and cell culture
H1299 cells were incubated in RPMI-1640 medium, and MCF7
cells were incubated in Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% heat inactivated fetal bovine serum (FBS)
and an antibiotic–antimycotic mix (all from Invitrogen) in a 5%
CO2 atmosphere at 37 C. For E2 (Sigma) treatment, FBS was pre-
treated with charcoal.
2.3. Glutathione S-transferase (GST) pull-down assay
GST-fused CAC1 protein was expressed in E. coli and puriﬁed on
glutathione–Sepharose beads (GE Healthcare) by standard(A)
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Bound proteins were detected by Western blotting (WB) using an
anti-ERa antibody (Santa Cruz Biotechnology).
2.4. Immunoﬂuorescence microscopy
The experimental procedures were carried out as described pre-
viously [11]. H1299 cells were seeded on culture chamber and
transfected with GFP-ERa and Myc-tagged CAC1. Cells were visual-
ized by immunoﬂuorescence microscopy (Carl Zeiss).2.5. Transient transfection and luciferase reporter assay
H1299 or MCF7 cells were seeded in a 6-well culture plate and
transiently transfected with ERE(3)-luciferase reporter and SV40-
driven-galactosidase (b-gal) expression vector. Depending on the
experimental conditions, ERa, CAC1, or LSD1 expression vector
was co-transfected using Lipofectamine with Plus Reagent (Invitro-
gen). Luciferase activity was measured with a luminometer accord-
ing to the manufacturer’s instructions (Promega) and normalized
to b-gal activity.2.6. Immunoprecipitation (IP) and WB
IP and WB were performed as previously described [12]. Brieﬂy,
lysates from transfected cells were incubated overnight at 4 C
with a 1:200 dilution of the indicated antibodies. After 2 h of incu-
bation at 4 C with A/G-agarose beads (Santa Cruz Biotechnology),
immune complexes were washed, released from the beads by boil-
ing, and then analyzed by WB using the indicated antibodies. For
WB, proteins were separated by electrophoresis on 8–10% sodium(B)
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membranes, and incubated with the following primary antibodies
(ERa, sc-7207; GFP, sc-8334; b-actin, sc-47778, Santa Cruz Bio-
technology; Flag M2, F3165, Sigma). The blots were then incubated
with peroxidase-conjugated mouse or rabbit IgG secondary anti-
bodies (Santa Cruz Biotechnology). The protein bands were de-
tected with an enhanced chemiluminescence (ECL) system (GE
Healthcare).
2.7. Real-time reverse transcription-polymerase chain reaction (RT-
PCR)
The experimental procedures were performed as previously de-
scribed [13]. Total RNA fromMCF7 cells was extracted using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions.
RNA (5 lg) was reverse-transcribed using Superscript II reverse
transcriptase (RT; Invitrogen) and random oligo (dT) primers
(Invitrogen). RT products were ampliﬁed using the following pri-
mer pair for the TFF1 coding sequence (133 bp): forward, 50-CCA
TGGAGAACAAGGTGATCTG-30 and reverse, 50-GTGACACCAGGAAAA
CCACAATT-30, and analyzed by the iQ™ SYBR Green Supermix and
Icycler CFX96 Real-Time PCR detection system (Bio-Rad). All geneMCF7
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2.8. Chromatin immunoprecipitation (ChIP)
ChIP analysis was conducted as previously described [13]. MCF7
cells were transfected with a Flag-empty or a Flag-CAC1 vector and
treated with or without 1 lM E2 for 30 min. Cross-linked protein–
chromatin complexes were recovered by IP with the indicated
antibodies, and the cross-linking was reversed according to Up-
state’s protocol (Millipore). DNA pellets were recovered and ana-
lyzed by PCR using a primer pair directed at the TFF1 promoter
region: forward, 50-GGCCATCTCTCACTATGAATC-30 and reverse,
50-GGCAGGCTCTGTTTGCTTAAA-30.
2.9. RNA interference (RNAi)
The CAC1 shRNA duplex sequences were as follows: sense, 50-
GATCCATGTGTATGCCAGCAGCACTTCAAGAGAGTGCTGCTGGCATAC
ACATTTTTTTGGAAA-30 and antisense, 50-AGCTTTTCCAAAAAAATG
TGTATGCCAGCAGCACTCTC TTGAAGTGCTGCTGGCATACACATG-30.E2+
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(Gibco-BRL) according to the manufacturer’s instructions. CAC1
depletion was veriﬁed by WB using an anti-CAC1 antibody
(Peptron).
2.10. Trypan blue exclusion assay
The trypan blue exclusion assay was carried out as previously
described [14]. MCF7 cells were transfected with a CAC1 and/or
LSD1 expression vector and were treated with 50 nM paclitaxel
(Sigma) for 36 h. Cells were treated with 0.4% trypan blue and
the number of cells (viable, unstained and non-viable, blue) was
counted.
3. Results and discussion
3.1. CAC1 interacts with ERa in a ligand-independent manner
It has been reported that CAC1 is a CDK2-assocaited cullin [15],
but its biological role is unclear. CAC1 sequence analysis revealed
that it contains two putative motifs: LMNVI and LQSIVPLFI, calledthe CoRNR box (L/IXXI/VI), and LMPLL, called the NR box (LXXLL)
(Fig. 1A). These motifs, responsible for NR interaction, are present
in corepressors and coactivators, respectively [16,17]. As CAC1 is
highly expressed in ERa-positive MCF7 breast cancer cells [15],
we examined whether CAC1 physically interacts with ERa. GFP-
tagged ERa was co-transfected with Flag empty or Flag-tagged
CAC1 in H1299 cells. IP with an anti-GFP antibody and subsequent
WB with an anti-Flag antibody indicated that CAC1 interacts with
ERa in the absence of the ligand E2 (Fig. 1B), whereas CAC1 binding
to ERawas diminished in the presence of E2. The E2-dependent re-
duced interaction was further conﬁrmed by a GST pull-down assay
in vitro (Fig. 1C). To further substantiate the interaction, we ex-
plored the subcellular distribution of CAC1 and ERa in H1299 cells.
Immunoﬂuorescence microscopy revealed that Myc-CAC1 and
GFP-ERa co-localized in the nucleus (Fig. 1D). Overall, these results
demonstrate that CAC1 physically associates with ERa in a ligand-
independent manner. This mode of CAC1 interaction is distinct
from not only ERa coactivators that bind in the presence of ligand,
but also from ERa corepressors (e.g., NCoR and SMRT) that interact
with antagonist-bound ERa. Indeed, the CAC1-ERa interaction was
greatly impaired in the presence of ERa antagonist, tamoxifen
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J. Kim et al. / FEBS Letters 587 (2013) 17–22 21(Supplementary Fig. 1). Therefore, we assume that CAC1 is the ﬁrst
identiﬁed ligand-independent ERa-binding partner, which is dis-
tinct from known ERa coregulators.
3.2. CAC1 represses ERa transcriptional activity
To determine the functional relevance of the interaction be-
tween CAC1 and ERa, we monitored the effect of CAC1 on ERa
transcriptional activity. ERa-positive MCF7 cells were co-transfec-
ted with an ERE-luciferase reporter and CAC1 in the presence of E2.
As shown in Fig. 2A, CAC1 greatly repressed ERa-mediated tran-
scriptional activity in a concentration-dependent manner. In con-
trast, CAC1 depletion by shRNA treatment resulted in markedly
increased ERa transcriptional activity (Fig. 2B). Consistent with
our interaction data, CAC1 knockdown also increased ERa activity
in the absence of E2. Next, we analyzed the effect of CAC1 on the
endogenous expression of the ERa target, TFF1 (pS2), in MCF7 cells
using real-time RT-PCR. The E2-induced TFF1 gene mRNA expres-
sion was signiﬁcantly reduced by CAC1 overexpression (Fig. 2C)
and augmented following CAC1 knockdown (Fig. 2D). We also ob-
served a similar effect of CAC1 on the expression of another ERa
target gene, Cathepsin D (Supplementary Fig. 2). These data,together with our binding data, suggest that CAC1 is a novel type
of ERa corepressor.
3.3. CAC1 CoRNR box is required for ERa inactivation
To map the domain responsible for ERa and CAC1 interaction,
we ﬁrst constructed ERa deletion mutants fused to GFP (Fig. 3A).
H1299 cells were co-transfected with Flag-CAC1 and GFP or GFP-
ERa deletion mutants. Subsequent IP assay indicated that the
ERa DBD was responsible for CAC1 binding (Fig. 3B). Furthermore,
we generated truncated CAC1 mutants, which contained three
putative motifs (CoRNR1, CoRNR2, and NR box; Fig. 3C). Initial IP
analysis revealed that the CAC1 fragment covering CoRNR1 and
CoRNR2 (amino acids 1–260) was sufﬁcient, but the fragment
including the NR box (amino acids 261–369) was not required
for ERa binding (data not shown). Therefore, further IP assays were
performed to determine whether the CoRNR box was required for
the interaction. As shown in Fig. 3C, CAC1 lacking CoRNR1 re-
mained bound to ERa, whereas the CoRNR2 mutant did not bind
ERa, suggesting that CAC1 CoRNR2 is critical for its interaction
with ERa. Subsequently, the role of CoRNR2 in ERa inactivation
was investigated using an ERE-luciferase reporter. Data shown in
22 J. Kim et al. / FEBS Letters 587 (2013) 17–22Fig. 3D indicated that CAC1 CoRNR2 but not CoRNR1, was required
to suppress ERa transcriptional activity. Overall, our data suggest
that CAC1 represses ERa activity by associating through the
CoRNR2 box.
3.4. CAC1 inhibits LSD1-enhanced ERa activity
Histone demethylase LSD1, associated with ERa, permits E2-
dependent gene activation by removing a methyl group from
methylated H3K9 (H3K9me), a repressive histone mark [18]. To
investigate the possibility that CAC1 is involved in LSD1-mediated
activation of ERa, we ﬁrst addressed whether CAC1 interacts with
LSD1. Co-transfection followed by IP demonstrated the interaction
between CAC1 and LSD1 (Fig. 4A). In addition, a luciferase assay
showed that CAC1 strongly suppressed LSD1-enhanced transcrip-
tional activity of ERa (Fig. 4B). This result was conﬁrmed by real-
time RT-PCR using TFF1 gene (Fig. 4C). To explore the molecular
mechanism underlying the reciprocal roles of CAC1 and LSD1 in
ERa activation, we performed ChIP analysis using the ER-respon-
sive TFF1 promoter under conditions of CAC1 overexpression or
depletion in MCF7 cells. The E2-dependent binding of ERa and
LSD1 to the promoter diminished, whereas H3K9 dimethylation
(H3K9me2) increased due to CAC1 overexpression (Fig. 4D). As ex-
pected, CAC1 bound to the TFF1 promoter in the absence of E2 and
the occupancy decreased in the presence of E2. In contrast, CAC1
knockdown increased the binding occupancies of ERa and LSD1,
leading to signiﬁcantly lower H3K9me2 accumulation (Fig. 4E).
These results were further quantitated by real-time PCR under
overexpression and knockdown conditions of CAC1 (Supplemen-
tary Fig. 3). No enrichments of ERa, CAC1, and LSD1 were detected
at the distal region of TFF1 promoter (Supplementary Fig. 4). In
addition, a similar binding or enrichment pattern was observed
when the promoter of GREB1, another ERa target gene, was used
as the PCR template (Supplementary Fig. 5). Taken together, these
data suggest that CAC1 inhibits LSD1 binding to the ERa target pro-
moter and increases the level of repressive histone mark
H3K9me2, resulting in suppressed ERa activity.
3.5. CAC1 sensitizes paclitaxel-induced cell death
Data from clinical trials or retrospective analyses indicate that
ER status might affect the efﬁcacy of chemotherapy [19]. Speciﬁ-
cally, ERa-expressing MCF7 breast cancer cells are highly resistant
to paclitaxel compared to ERa-negative breast cancer cells [20].
Thus, we determined the effect of CAC1 on paclitaxel resistance
in MCF7 cells by measuring paclitaxel-induced cell death. As
shown in Fig. 4F, CAC1 overexpression increased paclitaxel-in-
duced cell death, while the ERa-binding defective CAC1 mutant
(DCoRNR) was unaffected. In addition, LSD1 overexpression aug-
mented paclitaxel resistance compared to control cells. Again, co-
transfection of LSD1 and CAC1 rescued paclitaxel sensitivity to
the level of control cells, whereas CAC1 mutant DCoRNR was
defective for this rescue, highlighting the requirement of CAC1
binding to ERa for paclitaxel sensitivity. These data support that
CAC1, as an ERa corepressor, may be important in breast cancer
therapy by increasing paclitaxel sensitivity.
In summary, we identiﬁed a novel class of ERa corepressor
called CAC1. Our data indicated that CAC1 interacts with the ERa
DBD and inhibits ERa transcriptional activity. The CoRNR box of
CAC1 is critical for ERa binding and inactivation. Interestingly,
CAC1 also binds to histone demethylase LSD1, a known ERa coac-
tivator, and represses LSD1-enhanced ERa activity. This repression
may result from the reduced recruitment of LSD1 to the ERa-
responsive gene promoter by LSD1–CAC1 interaction. Finally, we
observed that CAC1 increases paclitaxel sensitivity in MCF7 cells,
which is paclitaxel resistant, due to ERa activation. From our data,we speculate that CAC1, a novel class of ERa corepressor, may be a
useful target in breast cancer therapy by its increasing paclitaxel
sensitivity.
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